ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CPHI vs RNAZ // REVENUE GROWTH (YOY)

China Pharma Holdings Inc. (NYSE) VS. TransCode Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CPHI 2 — RNAZ 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CPHI VS. RNAZ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CPHI RNAZ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin -3.20% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -11.40% -35.00% +23.60 CPHI /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 0.32% — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE -8.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 CPHI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.2 40.8 -0.64 RNAZ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $28.0M $29.3M -$1.3M RNAZ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CPHI REV RNAZ REV CPHI GROSS % RNAZ GROSS % CPHI FCF RNAZ FCF
FY 2025 $4.1M $0 -3.2% — $88.9K -$19.5M
FY 2024 $4.5M $0 -43.8% — -$444.5K -$13.4M
FY 2023 $7.0M $0 — — -$699.7K -$18.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CPHI // BETA —
RNAZ // BETA —